Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
100mg aspirin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Recurrent Acute Pancreatitis
1 trial -
100mg diclofenac
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Post-ERCP Acute Pancreatitis
1 trial -
11UCB-J PET Scan
BRIGHT MINDS BIOSCIENCES INC.
Opiate Dependence
1 trial -
18F-PSMA-1007
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
2L PEG
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Bowel Preparation Scale
1 trial -
30% Nitrous oxide
BRIGHT MINDS BIOSCIENCES INC.
Opioid-Related Disorders
2 trials -
5-gene classification model
Hospital Authority, Hong Kong
ABO Blood Type Incompatible Kidney Transplantation
1 trial -
68Ga-DOTA-NT-20.3
The First People's Hospital of Lianyungang
Pancreatic Ductal Adenocarcinoma
1 trial -
75 mg acetylsalicylic acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Preeclampsia
1 trial -
95% condensed proanthocyanidins from grape seed extract
United Therapeutics Europe Ltd
Iron Deficiency Anemia
1 trial -
99mTc-4BOH SPECT myocardial perfusion imaging
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
The First People's Hospital of Lianyungang
Neuromuscular Blockade
1 trial -
A+ HA(tm)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Knee Osteoarthritis
2 trials -
AIM-CHD Mobile Health Intervention
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Secondary Prevention of Coronary Heart Disease
1 trial -
ANKASCIN 568-P Red yeast rice capsules
Biotech Pharmaceutical Co.,
Hyperlipidemias
1 trial -
Accurate Prediction Artificial Intelligence Models
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Adiposity and Iron Requirements in Pregnancy (ADIPREG)
Disc Medicine
Iron Deficiency Anemia of Pregnancy
1 trial -
Aescin in Horse Chestnut
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Anorectal Disorder
1 trial -
Akkermansia Probiotics
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colo-rectal Cancer
1 trial -
Albumin paclitaxel/neutrophil drug
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Albumin-Bound Paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Carcinoma
1 trial -
Amino acid-derived lipids
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation Dermatitis
1 trial -
Amway Herbal Drink
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Skin Laxity
1 trial -
Anlotinib Hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources